Sanofi and Novo Nordisk, two of Europe’s health-care companies most exposed to the falling prices for insulin products in the all-important U.S. market, gave dramatically diverging outlooks in the third quarter, sending their stock prices in opposite directions.
from WSJ.com: US Business http://ift.tt/2eWVzDn
via IFTTT
No comments:
Post a Comment